|
Dr. Kirk earned his M.S. at the Massachusetts Institute of Technology in polymer science and his Ph.D. at the University of Florida in Materials Science and Engineering, particularly in drug delivery and bio-erodible devices. Most recently he has been consulting with a variety of biomedical companies on materials selection and process development. Prior to joining Nanotherapeutics he held the position of Research Manager at Regeneration Technologies, Inc. from 2001 to 2003 and Scientist positions at Vistakon and Genzyme. He joined Nanotherapeutics in 2004 as Director of the Manufacturing Department and oversees the newly FDA-approved bone graft product, OrigenTM DBM with Bioactive Glass Bone Graft. Dr. Kirk has presented over 30 abstracts and been involved in 6 patents in the fields of biomedical materials and polymers. | 